# Trade Mark Journal No.2026/035 28 August 2026

## WO0000001932149 (5)

Office of origin: United States of America

Date of International Registration:4 June 2026
Date of designation in the UK: 4 June 2026

Class 5
  Pharmaceuticals for the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), cancer, and obesity; pharmaceuticals for the treatment of life-threatening diseases; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics for use in the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), cancer, and obesity; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics that feature RNA as their active ingredient; pharmaceuticals, namely, small molecule therapeutics that induce changes in the chemical modifications of ribonucleic acid (RNA); pharmaceuticals, namely, viral vector therapeutics that induce changes in the chemical modifications of ribonucleic acid (RNA).

Tinos Therapeutics, Inc.

Representative: Nicole Kinsley FOLEY HOAG LLP, 155 Seaport Blvd., Boston NY 02210, UNITED STATES OF AMERICA